Cargando…

The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion

BACKGROUND: Extended criteria donor lungs deemed unsuitable for immediate transplantation can be reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can be successfully reconditioned and will function well post-operatively has not been established. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreasson, Anders S.I., Borthwick, Lee A., Gillespie, Colin, Jiwa, Kasim, Scott, Jonathan, Henderson, Paul, Mayes, Jonny, Romano, Rosalba, Roman, Marius, Ali, Simi, Fildes, James E., Marczin, Nandor, Dark, John H., Fisher, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578478/
https://www.ncbi.nlm.nih.gov/pubmed/28551353
http://dx.doi.org/10.1016/j.healun.2017.05.012
_version_ 1783260537130319872
author Andreasson, Anders S.I.
Borthwick, Lee A.
Gillespie, Colin
Jiwa, Kasim
Scott, Jonathan
Henderson, Paul
Mayes, Jonny
Romano, Rosalba
Roman, Marius
Ali, Simi
Fildes, James E.
Marczin, Nandor
Dark, John H.
Fisher, Andrew J.
author_facet Andreasson, Anders S.I.
Borthwick, Lee A.
Gillespie, Colin
Jiwa, Kasim
Scott, Jonathan
Henderson, Paul
Mayes, Jonny
Romano, Rosalba
Roman, Marius
Ali, Simi
Fildes, James E.
Marczin, Nandor
Dark, John H.
Fisher, Andrew J.
author_sort Andreasson, Anders S.I.
collection PubMed
description BACKGROUND: Extended criteria donor lungs deemed unsuitable for immediate transplantation can be reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can be successfully reconditioned and will function well post-operatively has not been established. This study assessed the predictive value of markers of inflammation and tissue injury in donor lungs undergoing EVLP as part of the DEVELOP-UK study. METHODS: Longitudinal samples of perfusate, bronchoalveolar lavage, and tissue from 42 human donor lungs undergoing clinical EVLP assessments were analyzed for markers of inflammation and tissue injury. Levels were compared according to EVLP success and post-transplant outcomes. Neutrophil adhesion to human pulmonary microvascular endothelial cells (HPMECs) conditioned with perfusates from EVLP assessments was investigated on a microfluidic platform. RESULTS: The most effective markers to differentiate between in-hospital survival and non-survival post-transplant were perfusate interleukin (IL)-1β (area under the curve = 1.00, p = 0.002) and tumor necrosis factor-α (area under the curve = 0.95, p = 0.006) after 30 minutes of EVLP. IL-1β levels in perfusate correlated with upregulation of intracellular adhesion molecule-1 in donor lung vasculature (R(2) = 0.68, p < 0.001) and to a lesser degree upregulation of intracellular adhesion molecule-1 (R(2) = 0.30, p = 0.001) and E-selectin (R(2) = 0.29, p = 0.001) in conditioned HPMECs and neutrophil adhesion to conditioned HPMECs (R(2) = 0.33, p < 0.001). Neutralization of IL-1β in perfusate effectively inhibited neutrophil adhesion to conditioned HPMECs (91% reduction, p = 0.002). CONCLUSIONS: Donor lungs develop a detectable and discriminatory pro-inflammatory signature in perfusate during EVLP. Blocking the IL-1β pathway during EVLP may reduce endothelial activation and subsequent neutrophil adhesion on reperfusion; this requires further investigation in vivo.
format Online
Article
Text
id pubmed-5578478
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55784782017-09-06 The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion Andreasson, Anders S.I. Borthwick, Lee A. Gillespie, Colin Jiwa, Kasim Scott, Jonathan Henderson, Paul Mayes, Jonny Romano, Rosalba Roman, Marius Ali, Simi Fildes, James E. Marczin, Nandor Dark, John H. Fisher, Andrew J. J Heart Lung Transplant Article BACKGROUND: Extended criteria donor lungs deemed unsuitable for immediate transplantation can be reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can be successfully reconditioned and will function well post-operatively has not been established. This study assessed the predictive value of markers of inflammation and tissue injury in donor lungs undergoing EVLP as part of the DEVELOP-UK study. METHODS: Longitudinal samples of perfusate, bronchoalveolar lavage, and tissue from 42 human donor lungs undergoing clinical EVLP assessments were analyzed for markers of inflammation and tissue injury. Levels were compared according to EVLP success and post-transplant outcomes. Neutrophil adhesion to human pulmonary microvascular endothelial cells (HPMECs) conditioned with perfusates from EVLP assessments was investigated on a microfluidic platform. RESULTS: The most effective markers to differentiate between in-hospital survival and non-survival post-transplant were perfusate interleukin (IL)-1β (area under the curve = 1.00, p = 0.002) and tumor necrosis factor-α (area under the curve = 0.95, p = 0.006) after 30 minutes of EVLP. IL-1β levels in perfusate correlated with upregulation of intracellular adhesion molecule-1 in donor lung vasculature (R(2) = 0.68, p < 0.001) and to a lesser degree upregulation of intracellular adhesion molecule-1 (R(2) = 0.30, p = 0.001) and E-selectin (R(2) = 0.29, p = 0.001) in conditioned HPMECs and neutrophil adhesion to conditioned HPMECs (R(2) = 0.33, p < 0.001). Neutralization of IL-1β in perfusate effectively inhibited neutrophil adhesion to conditioned HPMECs (91% reduction, p = 0.002). CONCLUSIONS: Donor lungs develop a detectable and discriminatory pro-inflammatory signature in perfusate during EVLP. Blocking the IL-1β pathway during EVLP may reduce endothelial activation and subsequent neutrophil adhesion on reperfusion; this requires further investigation in vivo. Elsevier 2017-09 /pmc/articles/PMC5578478/ /pubmed/28551353 http://dx.doi.org/10.1016/j.healun.2017.05.012 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Andreasson, Anders S.I.
Borthwick, Lee A.
Gillespie, Colin
Jiwa, Kasim
Scott, Jonathan
Henderson, Paul
Mayes, Jonny
Romano, Rosalba
Roman, Marius
Ali, Simi
Fildes, James E.
Marczin, Nandor
Dark, John H.
Fisher, Andrew J.
The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
title The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
title_full The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
title_fullStr The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
title_full_unstemmed The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
title_short The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
title_sort role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578478/
https://www.ncbi.nlm.nih.gov/pubmed/28551353
http://dx.doi.org/10.1016/j.healun.2017.05.012
work_keys_str_mv AT andreassonanderssi theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT borthwickleea theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT gillespiecolin theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT jiwakasim theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT scottjonathan theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT hendersonpaul theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT mayesjonny theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT romanorosalba theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT romanmarius theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT alisimi theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT fildesjamese theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT marczinnandor theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT darkjohnh theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT fisherandrewj theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT andreassonanderssi roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT borthwickleea roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT gillespiecolin roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT jiwakasim roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT scottjonathan roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT hendersonpaul roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT mayesjonny roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT romanorosalba roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT romanmarius roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT alisimi roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT fildesjamese roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT marczinnandor roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT darkjohnh roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT fisherandrewj roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion
AT roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion